Editorial: Translation of genetically engineered T cells in cancer immunotherapy

Ralf-Holger Voss; Hakim Echchannaoui; He Huang; Shao-An Xue

doi:10.3389/fimmu.2023.1278677

Editorial: Translation of genetically engineered T cells in cancer immunotherapy

Front Immunol. 2023 Sep 7:14:1278677. doi: 10.3389/fimmu.2023.1278677. eCollection 2023.

Authors

Ralf-Holger Voss¹, Hakim Echchannaoui^{2

3

4}, He Huang⁵, Shao-An Xue^{6

7}

Affiliations

¹ Institute of Immunology, Department of Research Center for Immunotherapy, Laboratory U. Sahin, University Medical Center (UMC) of the Johannes Gutenberg University, Mainz, Germany.
² Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
³ German Cancer Consortium partner site Frankfurt/Mainz, Mainz, Germany.
⁴ University Cancer Center Mainz, Mainz, Germany.
⁵ Institute of Hematology, Zhejiang University, Hangzhou, China.
⁶ Surgery, Medical School, Faculty of Medical Sciences, University College London, London, United Kingdom.
⁷ Genetic Engineering Laboratory, School of Biological & Environmental Engineering, Xi'An University, Xi'An, China.

No abstract available

Keywords: CAR toxicity; CAR-T; TCR-T; cancer immunotherapy; genetic/cellular engineering; genome editing; immunosuppression; tumor specific/associated antigens.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Neoplasms* / genetics
Neoplasms* / therapy
T-Lymphocytes*

Grants and funding

SAX is supported by the National Natural Science Foundation of China (NSFC-81972883).